Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GEOVAX LABS, INC.

(GOVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

After Hours Watch List Scorecard: GOVX, LCID, LFMD

09/29/2021 | 05:21pm EST


ę MT Newswires 2021
All news about GEOVAX LABS, INC.
12/03GeoVax Says Investigational Vaccines Produce Immune Response Against Two Hemorrhagic Fe..
MT
12/03GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Con..
AQ
12/03GeoVax Labs, Inc. Presents Hemorrhagic Fever Vaccine Data at World Vaccine & Immunother..
CI
12/01GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress
AQ
11/17GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress
AQ
11/16GeoVax Labs Gets US Notice of Allowance for Cancer Vaccine Patent; Shares Surge
MT
11/16GeoVax Receives Notice of Allowance for Cancer Vaccine Patent
AQ
11/16GeoVax Labs, Inc. Receives Notice of Allowance for Cancer Vaccine Patent
CI
11/12GEOVAX LABS : Reports 2021 Third Quarter Financial Results and Provides Corporate Update -..
PU
11/12GEOVAX LABS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosur..
AQ
More news
Analyst Recommendations on GEOVAX LABS, INC.
More recommendations
Financials (USD)
Sales 2021 0,22 M - -
Net income 2021 -7,14 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,13x
Yield 2021 -
Capitalization 23,5 M 23,5 M -
Capi. / Sales 2021 107x
Capi. / Sales 2022 -
Nbr of Employees 8
Free-Float 91,8%
Chart GEOVAX LABS, INC.
Duration : Period :
GeoVax Labs, Inc. Technical Analysis Chart | GOVX | US3736785078 | MarketScreener
Technical analysis trends GEOVAX LABS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 3,69 $
Average target price 10,00 $
Spread / Average Target 171%
EPS Revisions
Managers and Directors
David A. Dodd Chairman, President & Chief Executive Officer
Mark W. Reynolds Chief Financial Officer & Secretary
Harriet Latham Robinson Chief Scientific Officer-Emeritus
Mark J. Newman Chief Scientific Officer
Dean G. Kollintzas Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GEOVAX LABS, INC.17.16%24
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298